PYCNOVID Trial Baseline Participant Characteristics for Post-COVID-19 Condition

The PYCNOVID randomized controlled trial collected data from 150 adults with post-COVID-19 condition, 74.7% of whom were female. Data includes participant characteristics at baseline, collected approximately two weeks after screening, as part of a study evaluating the 30-second sit-to-stand test. The dataset was authored by Julia Braun and last updated in May 2026.

Use Cases

• Analyzing baseline characteristics of a post-COVID-19 condition cohort based on the described participant demographics.
• Assessing test-retest reliability of functional capacity measures based on the described ICC and Bland-Altman analysis.
• Estimating minimal detectable change for clinical assessments based on the reported MDC95 of 4.25 repetitions.
• Investigating correlations between functional performance and symptoms based on the described weak correlations with physical activity and PCC-related symptoms.

Strengths

• Data from 150 adult participants provides a specific cohort size.
• Dataset is associated with a registered clinical trial (NCT05890534), providing a clear research context.
• The 30-second sit-to-stand test was reported as safe with no adverse events and feasible.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect selection bias inherent to a single clinical trial population.

Provenance

Source

figshare

Collection Method

Collected as part of the PYCNOVID randomized controlled trial.

Time Range

Data collected at screening, baseline (~2 weeks post-screening), and 12-week follow-up.

Freshness

Last updated 2026-05-12 17:48:07